Bio-Techne Corporation (TECH)

Bio-Techne Corporation (TECH) is a healthcare company (biotechnology) based in the United States. The share price is $72.79, down 0.01% on the day, which values the company at $11.43B. Price as of 17 Nov 2026, 17:15 UTC, from Yahoo Finance.

Key facts

Share price
$72.79−0.01% today
Market value
$11.43B
P/E ratio
66.8×last 12 months
Forward P/E
31.5×
Dividend yield
0.33%
Funk Score
56/100
Against its own history
Above its usual priceusual price $63.41
200-week average
$67.698% above

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Bio-Techne Corporation in more detail

TECH trades at 66.8× its last twelve months' earnings, 31.5× next year's expected earnings, 9.3× sales. Measured against its own history, the price is 15% above what its usual multiples would imply ($63.41) — above its usual price. It sits 8% above its 200-week average of $67.69.

Over the last five fiscal years Bio-Techne Corporation has compounded revenue 5.5% a year, earnings per share 5.9% a year, free cash flow -3.1% a year. Its Funk Score is 56 out of 100 (financial strength 9.2, profitability 6.4, growth 3.5, value 3.2, each out of 10).

In its favour: Altman Z in the safe zone; Strong Piotroski score.

7 of the superinvestors tracked here hold TECH, including Sequoia Fund team (3.9% of the portfolio), Wallace Weitz (1.3% of the portfolio), Lee Ainslie (1.0% of the portfolio).

Superinvestors holding TECH

7 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:TECH vs RGEN (Bio-Techne Corporation vs Repligen)TECH vs UHS (Bio-Techne Corporation vs Universal Health Services)TECH vs HALO (Bio-Techne Corporation vs Halozyme Therapeutics)TECH vs DVA (Bio-Techne Corporation vs DaVita)TECH vs BMRN (Bio-Techne Corporation vs BioMarin Pharmaceutical)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Bio-Techne Corporation (TECH): questions and answers

What is TECH's P/E ratio?

Bio-Techne Corporation trades at 66.8× its last twelve months' earnings and 31.5× next year's expected earnings. At its fiscal year-ends over the past 18 years the P/E ranged from 19.5× to 129.4×, with a median of 45.0×.

What is TECH's PEG ratio?

Bio-Techne Corporation's PEG ratio is 2.18 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Bio-Techne Corporation's market cap?

Bio-Techne Corporation is valued at $11.43B at a share price of $72.79.

Is TECH overvalued or undervalued?

Against its own history, TECH is above its usual price: the price is 15% above the $63.41 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is TECH above its 200-week moving average?

Yes. TECH is 7.5% above its 200-week average of $67.69. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Bio-Techne Corporation growing?

Over the last five fiscal years Bio-Techne Corporation's revenue grew 5.5% a year and its earnings per share 5.9% a year; over ten years revenue grew 9.3% a year.

Cite this page

Funkfolio, “Bio-Techne Corporation (TECH) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/TECH

Underlying data: Yahoo Finance; company filings with the SEC.